HTB

Conference reports

Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

Bioavailability of Thai generic lopinavir/ritonavir

XVIII International Drug Resistance Workshop, 9-13 June 2009, Florida

Transmitted multidrug-resistant HIV persists in PBMC DNA for years

Low-level Q148R in people without integrase inhibitor experience

Cut-offs suggested for predicting efavirenz failure with low-level K103N

Lower M184V rates with FTC/TDF than with 3TC/TDF

HBV resistance to lamivudine at undetectable and low levels of viremia

15th Annual Conference of the British HIV Association (BHIVA), 1-3 April 2009, Liverpool

Superinfection identified in 2 out of 8 patients with unexpected viral load increases

Peripheral DEXA scans to identify rates of reduced bone mineral density

Vitamin D deficiency, supplementation and tenofovir

High rate of lost and untested TB biopsy samples and low screening for latent TB

16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

Intensive smoking cessation programme reports limited success at 6 months

HDL particle concentration predicts cardiovascular disease in SMART

No effect of hormonal contraception on HIV disease progression in large multi-country cohort

Pregnancy, family planning, and HIV acquisition in HPTN 039

Progression and regression of pre-malignant cervical lesions in HIV-positive women from Soweto

CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

HIV testing of infants at immunisation clinics in Kwazulu-Natal

Rapid HIV disease progression in South African infants co-infected with cytomegalovirus (CMV)

Pharmacokinetic studies in very young infants

Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

PI-based ART in children with HIV and HIV/TB coinfection in South Africa

Etravirine dose selection in children aged 6 to 17

Preliminary results from first paediatric raltegravir study

10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

Efavirenz lowers levels of darunavir given as 900/100mg once daily with ritonavir

How much (or how little) ritonavir do you need to boost another PI?

Genetic markers linked to early discontinuation of three antiretrovirals

4th South African AIDS Conference, 31 March-3 April 2009, Durban, South Africa

HAART coverage and unmet need in South Africa

16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

HIV infection in the brain: a long-term limitation of HAART?

When to start HAART – a key research question with the least available data

Major studies rule out any benefit of Interleukin-2 (IL-2): results from ESPRIT and SILCAAT

Higher rates of non-AIDS cancers in HIV positive people

Effect of breast feeding vs formula feeding on maternal health

PEPI-Malawi

Premature delivery and mother-to-child HIV transmission: a risk/benefit analysis among women receiving HAART

Risk factors for adverse pregnancy outcomes in Botswana

Higher risk of transmission with delayed control of maternal viral load despite viral loads of <500 copies/mL at delivery

Lopinavir/r containing regimen superior to nevirapine containing regimen in women previously exposed to single dose nevirapine

Covering the nevirapine tail

Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes

High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana

Children on HAART do extremely well at South African clinic

New boosting alternatives to ritonavir: GS-99350 and SPI-452

Interactions with raltegravir: with twice-daily atazanavir and standard dose lamotrigine

Effect of tenofovir on abacavir phosphorylation

Nevirapine: fluconazole and TB treatment

PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy

Identification of drug interactions in clinical practice

Effect of substance abuse on ART pharmacokinetics

9th International Congress on Drug Therapy in HIV Infection, 9-13 November 2008, Glasgow

Summary of antiretroviral studies at Glasgow

The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy

Initial results from PENTA 11 trial of planned treatment interruption

Inflammation and coagulation markers askew in children with higher HIV RNA

Dosing of lopinavir/ritonavir in the CHIPS cohort

Number needed to treat to harm (NNTH) analysis of impact of underlying cardiovascular factors on risk of abacavir-related heart attack

Bone disease and HIV

Post navigation